Deubiquitinase OTUD5 promotes hepatitis B virus replication by removing K48-linked ubiquitination of HBV core/precore and upregulates HNF4ɑ expressions by inhibiting the ERK1/2/mitogen-activated protein kinase pathway
-
Published:2023-10-28
Issue:11
Volume:80
Page:
-
ISSN:1420-682X
-
Container-title:Cellular and Molecular Life Sciences
-
language:en
-
Short-container-title:Cell. Mol. Life Sci.
Author:
Lou Bin,
Ma Guanghua,
Yu Xiaopeng,
Lv Feifei,
Xu Fanjie,
Sun Chengdi,
Chen YuORCID
Abstract
AbstractHepatitis B virus (HBV) infection is a major public health problem worldwide, causing nearly one million deaths annually. OTUD5 is a deubiquitinase associated with cancer development and innate immunity response. However, the regulatory mechanisms of OTUD5 underlying HBV replication need to be deeply elucidated. In the present investigation, we found that HBV induced significant up-regulation of OTUD5 protein in HBV-infected cells. Further study showed that OTUD5 interacted with HBV core/precore, removing their K48-linked ubiquitination chains and protecting their stability. Meanwhile, overexpression of OTUD5 could inhibit the MAPK pathway and then increase the expression of HNF4ɑ, and ERK1/2 signaling was required for OTUD5-mediated activation of HNF4α, promoting HBV replication. Together, these data indicate that OTUD5 could deubiquitinate HBV core protein degradation by its deubiquitinase function and promote HBV activity by up-regulating HNF4α expression via inhibition of the ERK1/2 pathway. These results might present a novel therapeutic strategy against HBV infection.
Funder
Zhejiang Natural Science Foundation of China
National 863 Program for the Biological and medical technology
National Key Programs for Infectious Diseases of China
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Cellular and Molecular Neuroscience,Pharmacology,Molecular Biology,Molecular Medicine
Reference35 articles.
1. World Health Organization. Global hepatitis report, 2017. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed 30 Sept 2017
2. Beasley RP (1988) Hepatitis B virus. The major etiology of hepatocellular carcinoma. J Cancer 61:1942–1956
3. Ma G, Lou B, Lv F, Zhao D, Zhang Z, Chen Y (2020) HBcrAg and pg RNA and the therapeutic effect in HBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNA is a powerful predictor of response. J Viral Hepat 27(8):837
4. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z et al (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 11:1
5. Tan G, Song H, Xu F, Cheng G (2018) When hepatitis B virus meets interferons. Front Microbiol 9:1611